Last updated: February 17, 2026
What is the drug with NDC 52536-0886?
The drug identified by NDC 52536-0886 is Vyepti (eptinezumab), a monoclonal antibody developed by Lundbeck. It is approved by the FDA for the preventive treatment of migraine in adults. Vyepti is administered via intravenous infusion every three months. It is a part of the calcitonin gene-related peptide (CGRP) inhibitor class.
Market Landscape
Prevalence & Demand
- Migraine prevalence affects approximately 12-15% of the global population, with an estimated 39 million Americans experiencing migraines.
- The target patient population for Vyepti is adult migraine sufferers seeking preventive therapy.
- The migraine prevention segment sees substantial growth, expected to expand at a compound annual growth rate (CAGR) of 4.2% from 2022 to 2030 [1].
Competitive Dynamics
- Vyepti competes primarily with other CGRP inhibitors: Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality), and the oral Atogepant.
- Unlike subcutaneous options, Vyepti's intravenous route allows for quarterly dosing, which can influence patient adherence and preference.
- The competitive landscape is influenced by reimbursement policies, physician adoption, and patient preference for administration routes.
Key Market Players
| Drug |
Company |
Administration |
Year FDA Approved |
Estimated 2022 Sales (USD) |
| Vyepti |
Lundbeck |
IV, quarterly |
2020 |
~$150 million |
| Aimovig |
Amgen/Novartis |
SubQ, monthly |
2018 |
~$900 million |
| Ajovy |
Teva |
SubQ, quarterly |
2018 |
~$400 million |
| Emgality |
Eli Lilly |
SubQ, monthly |
2018 |
~$350 million |
| Atogepant (oral) |
AbbVie |
Oral daily |
2021 |
Data emerging |
Market Projections
- The global migraine prophylactic drugs market is projected to reach $4.5 billion by 2027 [2].
- Vyepti's role is expected to increase, particularly among patients who prefer intravenous infusions or have contraindications to subcutaneous injections.
- Adoption trends show a growing shift toward targeted monoclonal antibodies, accounting for over 60% of preventive migraine treatment sales by 2022 [3].
Pricing Trends and Projections
Current Pricing
- Average wholesale price (AWP) for Vyepti per infusion is approximately $2,500 - $3,000.
- Payers often negotiate discounts, limiting the effective price for insurers and pharmacy benefit managers (PBMs).
Comparison with Competitors
| Drug |
Typical MSRP per Dose |
Route |
Dosing Frequency |
Approximate Annual Cost (USD) |
| Vyepti |
$2,800 |
IV quarterly |
4 infusions/year |
~$11,200 |
| Aimovig |
$6,900 (monthly) |
SubQ monthly |
12 doses/year |
~$82,800 |
| Ajovy |
$7,400 (quarterly) |
SubQ quarterly |
4 doses/year |
~$29,600 |
| Emgality |
$6,900 (monthly) |
SubQ monthly |
12 doses/year |
~$82,800 |
Pricing Trends & Future Outlook
- As competition intensifies, market pressures are likely to push prices downward, particularly for high-cost injectable drugs.
- Pharmacoeconomic evaluations could influence formulary placements, leading to negotiated discounts.
- The upcoming approval of biosimilars or alternative delivery methods could further reduce prices.
- It is expected that the net cost for payers will decrease by approximately 10-15% annually over the next 3-5 years due to increased competition and market entry pressure.
Regulatory and Reimbursement Environment
- Reimbursement policies favor effective, convenient therapies.
- CMS and private insurers are increasingly emphasizing cost-effective treatments.
- Pricing negotiations and value-based agreements may influence the final net price delivered to payers.
Key Takeaways
- Vyepti has a niche position as an intravenous preventive therapy for migraine, with a differentiated dosing schedule.
- The U.S. market for migraine prevention drugs is projected to reach over $4.5 billion by 2027, with Vyepti's share gradually increasing.
- Current pricing hovers around $2,800 per infusion, with potential to decrease due to competitive pressures.
- Adoption will depend on payer acceptance, clinician familiarity, and patient preference for IV administration.
- Price reductions of 10-15% annually are likely in the coming years, driven by market competition and formulary negotiations.
FAQs
1. How does Vyepti compare to other CGRP inhibitors in efficacy?
Clinical trials show comparable efficacy across CGRP inhibitors. Vyepti achieves approximately a 50% reduction in monthly migraine days, similar to other monoclonal antibodies.
2. What is the typical patient profile for Vyepti?
Patients experiencing frequent migraines, especially those who prefer or require intravenous infusions or who have contraindications to subcutaneous therapies.
3. Will Vyepti price decrease significantly?
Potentially yes, with increased market competition and payer pressure. Expected annual price declines are around 10-15% over the next 3-5 years.
4. How does dosing frequency influence market adoption?
Quarterly infusion may improve adherence over monthly injections, but convenience favors subcutaneous options; thus, market share gains depend on clinician and patient preferences.
5. Are biosimilars or generics a concern for Vyepti?
As a monoclonal antibody biologic, biosimilars may enter the market, but biosimilar development for Vyepti would require substantial time. Patent protections could delay biosimilar entry until after 2030.
References
[1] MarketsandMarkets. "Migraine Drugs Market," 2022.
[2] Grand View Research. "Migraine Drugs Market Size, Share & Trends," 2022.
[3] Evaluate Pharma. "Monoclonal Antibodies in Migraine Prevention," 2022.
End of analysis.
